Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Blood (2024) 144 (Supplement 1): 338.

https://doi.org/10.1182/blood-2024-199868

Published: 2024

Journal Articles

The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma: A Supplementary Analysis of JCOG0601

Takahiro Nakashima, Tomotaka Suzuki, Gakuto Ogawa, Kazuyuki Shimada, Tsutomu Kobayashi, Dai Maruyama, Wataru Munakata, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Hirokazu Nagai

Blood (2023) 142 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2023-174354

Published: 2023

Journal Articles

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Blood (2023) 142 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2023-178551

Published: 2023

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601

Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai

Blood (2023) 142 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2023-173433

Published: 2023

Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 557–560.

https://doi.org/10.1182/blood-2022-159123

Published: 2022

Journal Articles

Copy Number Alterations of Chromosome 9p24.1 in Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received ABVD: An Ancillary Analysis of Multi-Center Retrospective Study in Japan (HORIZON study)

Blood (2022) 140 (Supplement 1): 11890–11892.

https://doi.org/10.1182/blood-2022-164977

Published: 2022

Journal Articles

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Masaki Ri, Shimon Nakashima, Miki Nakajima, Shinsuke Iida, Dai Maruyama, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 12647–12649.

https://doi.org/10.1182/blood-2022-156875

Published: 2022

Journal Articles

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Takashi Watanabe, Kensei Tobinai, Ｍasashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Yoshihiro Matsuno, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 3615–3617.

https://doi.org/10.1182/blood-2022-159967

Published: 2022

Journal Articles

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Blood (2022) 140 (Supplement 1): 3718–3720.

https://doi.org/10.1182/blood-2022-157006

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 9368–9372.

https://doi.org/10.1182/blood-2022-159425

Published: 2022

Journal Articles

Clinical Outcomes of Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received an ABVD Regimen: A Multi-Center Retrospective Study in Japan (HORIZON study)

Blood (2021) 138 (Supplement 1): 2451.

https://doi.org/10.1182/blood-2021-146340

Published: 2021

Journal Articles

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Noriko Fukuhara, Won Seog Kim, Dok Hyun Yoon, Eiju Negoro, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai

Blood (2021) 138 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2021-145512

Published: 2021

Journal Articles

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Blood (2019) 134 (Supplement_1): 350.

https://doi.org/10.1182/blood-2019-126798

Published: 2019

Journal Articles

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Masaki Ri, Shinsuke Iida, MD PhD, Dai Maruyama, MD PhD, Kosuke Saito, Yoshiro Saito, Satoshi Osaga, Masahiro Tohkin, Naoki Miyata, Kensei Tobinai, MD PhD, Noriko Fukuhara, MD PhD, Kana Miyazaki, MD PhD, Yosuke Minami, MD PhD, Norifumi Tsukamoto, MD PhD, Hideki Tsujimura, MD PhD, Makoto Yoshimitsu, MD PhD, Kenichi Miyamoto, Kunihiro Tsukasaki, MD PhD, Hirokazu Nagai, MD PhD

Blood (2019) 134 (Supplement_1): 3156.

https://doi.org/10.1182/blood-2019-122218

Published: 2019

Journal Articles

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Blood (2018) 132 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2018-99-110201

Published: 2018

Journal Articles

Possibility of a Risk-Adapted Treatment Strategy for Untreated Aggressive Adult T-Cell Leukemia-Lymphoma (ATL) Based on the ATL Prognostic Index: A Supplementary Analysis of the JCOG9801 Study

Kosuke Toyoda, MD, Kunihiro Tsukasaki, MD PhD, Ryunosuke Machida, Tomohiro Kadota, MD PhD, Takuya Fukushima, MD PhD, Kenji Ishitsuka, MD PhD, Dai Maruyama, MD PhD, Hirokazu Nagai, MD PhD

Blood (2018) 132 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2018-99-112734

Published: 2018

Journal Articles

Genome Analysis of a Mantle Cell Lymphoma Case with t(5;18)(p15;q21) Lacking the Translocation Involving Cyclin D1

Kazumi Hagiwara, PhD, Takashi Tokunaga, MD PhD, Hiroatsu Iida, MD PhD, Hirokazu Nagai, MD PhD

Blood (2018) 132 (Supplement 1): 5303.

https://doi.org/10.1182/blood-2018-99-118265

Published: 2018

Journal Articles

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Masahiro Sekimizu, MD PhD, Reiji Fukano, MD PhD, Ilseung Choi, MD PhD, Akiko Kada, PhD, Akiko Saito, MD, Ryuta Asada, PhD, Tetsuya Mori, MD PhD, Hirokazu Nagai, MD PhD

Blood (2018) 132 (Supplement 1): 2924.

https://doi.org/10.1182/blood-2018-99-112708

Published: 2018

Journal Articles

Phase 1/2 Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Venetoclax in Japanese Subjects with Chronic Lymphocytic Leukemia

Kiyohiko Hatake, MD PhD, Kazuhito Yamamoto, MDPhD, Noriko Fukuhara, MD PhD, Shigeru Kusumoto, MD, Koji Izutsu, MD, PhD, Ilseung Choi, MD, Hirokazu Nagai, MD PhD, Hideyuki Honda, BS, Junjiro Saeki, MS, Andrew W. Roberts, MS, Paulo Maciag, MD PhD, Suresh Agarwal, MS, PhD RPh, Ahmed Hamed Salem, PhD, Kevin J. Freise, PhD, Tsukasa Kiriyama, PharmD, BSc, Kensei Tobinai, MD PhD

Blood (2017) 130 (Supplement 1): 5352.

https://doi.org/10.1182/blood.V130.Suppl_1.5352.5352

Published: 2017

NARROW

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma: A Supplementary Analysis of JCOG0601

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Copy Number Alterations of Chromosome 9p24.1 in Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received ABVD: An Ancillary Analysis of Multi-Center Retrospective Study in Japan (HORIZON study)

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Clinical Outcomes of Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received an ABVD Regimen: A Multi-Center Retrospective Study in Japan (HORIZON study)

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Possibility of a Risk-Adapted Treatment Strategy for Untreated Aggressive Adult T-Cell Leukemia-Lymphoma (ATL) Based on the ATL Prognostic Index: A Supplementary Analysis of the JCOG9801 Study

Genome Analysis of a Mantle Cell Lymphoma Case with t(5;18)(p15;q21) Lacking the Translocation Involving Cyclin D1

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Phase 1/2 Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Venetoclax in Japanese Subjects with Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only